Drugs / Anti-VEGFR2 CAR CD8 plus PBL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01218867 | Nov 2010 → Sep 2014 | kidney cancer, metastatic malignant neoplasm, metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-VEGFR2 CAR CD8 plus PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01218867 ↗ |
| Modality | Cell therapy | “cell therapy using anti-VEGFR2 gene modified tumor white blood cells” NCT01218867 ↗ |
| Route | Intravenous | “followed by intravenous infusion of ex vivo CAR gene-transduced CD8+ PBMC” NCT01218867 ↗ |